Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma.

被引：0
|
作者：
Kudchadkar, Ragini Reiney [1 ]
Gallenstein, Donna [1 ]
Martinez, Alberto J. [1 ]
Yu, Bin [1 ]
Weber, Jeffrey S. [1 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8582
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
    Michael A Postow
    Diana M Cardona
    Janis M Taube
    Robert A Anders
    Clive R Taylor
    Jedd D Wolchok
    Margaret K Callahan
    Michael A Curran
    Alexander M Lesokhin
    Joseph F Grosso
    Christine E Horak
    John Cogswell
    Jason S Simon
    Ashok K Gupta
    Mario Sznol
    Journal of Translational Medicine, 12 (Suppl 1)
  • [12] EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL
    Gettinger, Scott
    Horn, Leora
    Antonia, Scott J.
    Spigel, David R.
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph M.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok
    Brahmer, Julie R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S909 - S909
  • [13] Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.
    Topalian, Suzanne Louise
    Sznol, Mario
    Brahmer, Julie R.
    McDermott, David F.
    Smith, David C.
    Gettinger, Scott N.
    Taube, Janis M.
    Drake, Charles G.
    Pardoll, Drew M.
    Powderly, John D.
    Carvajal, Richard D.
    Sosman, Jeffrey Alan
    Atkins, Michael B.
    Antonia, Scott J.
    Spigel, David R.
    Lawrence, Donald P.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Wigginton, Jon M.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [14] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
    Antonia, Scott Joseph
    Gettinger, Scott N.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Chen, Allen C.
    Ready, Neal
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [15] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538)
    Sznol, Mario
    Kluger, Harriet M.
    Hodi, F. Stephen
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [16] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Sznol, Mario
    Kluger, Harriet M.
    Hodi, F. Stephen
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [17] A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
    Segal, Neil Howard
    Hodi, F. Stephen
    Sanborn, Rachel E.
    Gajewski, Thomas
    Wolchok, Jedd D.
    Urba, Walter John
    Fox, Bernard A.
    Topallan, Suzanne Louise
    Pardoll, Drew M.
    Kollia, Georgia
    McDonald, Dan
    Kim, Su Young
    Sharfman, William Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [18] Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).
    Brahmer, Julie R.
    Horn, Leora
    Antonia, Scott J.
    Spigel, David R.
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [19] Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis
    Sangro, Bruno
    Crocenzi, Todd S.
    Welling, Theodore Hobart
    Inarrairaegui, Mercedes
    Prieto, Jesus
    Fuertes, Carmen
    Delanty, Laurie
    Feely, William
    Anderson, Jeffrey
    Grasela, Dennis M.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Melero, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [20] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Wolchok, Jedd D.
    Kluger, Harriet M.
    Callahan, Margaret K.
    Postow, Michael Andrew
    Gordon, Ruth Ann
    Segal, Neil Howard
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Reed, Kathleen
    Burke, Matthew M.
    Caldwell, Anne
    Kronenberg, Stephanie Anne
    Agunwamba, Blessing
    Feely, William
    Hong, Quan
    Horak, Christine E.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345